Atrial Fibrillation ; prevention & control ; Humans ; Primary Prevention

Atrial Fibrillation/complications* ; Humans ; Singapore ; Stroke/prevention & control* ; Thailand

Atrial Fibrillation/complications* ; Cardiomyopathy, Hypertrophic/complications* ; Humans ; Thromboembolism/prevention & control*

There have been recent advances in the hyperacute treatment and secondary prevention of ischemic stroke. Thrombolysis with intravenous tissue plasminogen activator has been approved for a 3 to 4.5 hour time window, but the recent controversy over the optimal dose has not been resolved. Five endovascular trials published in 2015 have shown dramatically positive results. Regarding secondary prevention of ischemic stroke, a study suggesting the beneficial effect of a short course of dual antiplatelet therapy has been published. Non-vitamin K antagonist oral anticoagulation agents have been approved for stroke prevention in non-valvular atrial fibrillation. Here, we review these recent advances in ischemic stroke management.
Anticoagulants ; Atrial Fibrillation ; Endovascular Procedures ; Platelet Aggregation Inhibitors ; Secondary Prevention ; Stroke* ; Tissue Plasminogen Activator

Atrial fibrillation (AF) is the most common arrhythmia and is associated with increased cardiovascular morbidity and mortality. The anti-arrhythmic effect of statins on AF prevention appears to be highly significant in most clinical studies. However, some discrepancies do exist among different clinical studies. Different clinical settings and types of stains used may explain these differences between trials. The CHADS2 and CHA2DS2VASc scoring systems have been used for stroke risk stratification in AF patients. The recent study suggested that these scores can also be used to guide statin therapy for AF prevention. Patients with higher scores had a higher risk of developing AF and gained more benefits from statins therapy than those with lower scores. This review article focused on the ability of these scores to predict AF prevention by statins.
Arrhythmias, Cardiac ; Atrial Fibrillation* ; Coloring Agents ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors* ; Mortality ; Primary Prevention* ; Stroke

Animals ; Atrial Fibrillation ; etiology ; prevention & control ; surgery ; Catheter Ablation ; Coronary Sinus ; anatomy & histology ; physiology ; Humans

Anticoagulants ; therapeutic use ; Atrial Fibrillation ; complications ; Humans ; Thromboembolism ; etiology ; prevention & control

Anticoagulants ; therapeutic use ; Atrial Fibrillation ; etiology ; genetics ; therapy ; Catheter Ablation ; Humans ; Thromboembolism ; prevention & control ; United States

Anticoagulants ; therapeutic use ; Atrial Fibrillation ; therapy ; Catheter Ablation ; Europe ; Humans ; Stroke ; prevention & control

Adult ; Aged ; Atrial Fibrillation ; etiology ; prevention & control ; Bronchoalveolar Lavage ; adverse effects ; Humans ; Male ; Middle Aged